preparation of [4-amino-2-[(1-methanesulfonylpiperidin-4-yl)amino]pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl)methanone_ kain industrial additives
background and overview[1] r547 ([4-amino-2-[(1-methanesulfonylpiperidin-4-yl)amino]pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl) methone) is a potent inhibitor of cdks 1, 2, 4, 7, and 9 and has shown broad antitumor activity in preclinical models. the phase ia study evaluated safety, pharmacokinetic (pk) and pharmacodynamic (pd) endpoints. the method is: r547 ([4-amino-2-[(1-methanesulfonylpiperidin-4-yl)amino]pyrimidin-5-yl](2,3-difluoro-6-methoxyphenyl) ketone) given as a 90 or 180 minute infusion on d1,…

